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Background-—Assessing and optimizing cardiovascular health (CVH) early in life, such as in pregnancy, could lead to a longer
lifetime spent in better CVH and reduce the risk of cardiovascular disease. This might especially beneﬁt women with a hypertensive
disorder of pregnancy (HDP) who are more likely to develop atherosclerosis and cardiovascular disease. We hypothesized that CVH
in pregnancy is related to later life CVH and carotid intima-media thickness (CIMT), and that these associations differ between
women with a normotensive pregnancy and women with an HDP.
Methods and Results-—This study was conducted within the prospective population-based Generation R Study. CVH in pregnancy
was based on 5 metrics (blood pressure, total-cholesterol, glucose, smoking, and body mass index). Postpartum CVH additionally
included physical activity and diet scores, according to the American Heart Association classiﬁcation. Postpartum CVH and CIMT
were measured 10 years after pregnancy. Results were analyzed for women with a normotensive pregnancy and those with an
HDP. Women with a normotensive pregnancy (n=1786) and women with an HDP (n=138) were evaluated from early pregnancy
until 10 years postpartum. Better CVH in early pregnancy was associated with a smaller CIMT and better postpartum CVH in all
women, especially in those with an HDP (CIMT: 9.82 lm [95% CI: 17.98, 1.67]).
Conclusions-—Already in pregnancy, better CVH is associated with a smaller CIMT and better CVH 10 years postpartum, especially
in women with an HDP. As pregnancy is an incentive for women to improve lifestyle, assessing CVH in pregnancy might help
improve postpartum CVH and reduce cardiovascular disease risk. ( J Am Heart Assoc. 2019;8:e011394. DOI: 10.1161/JAHA.
118.011394.)
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W omen with a hypertensive disorder of pregnancy, suchas gestational hypertension and preeclampsia, have a
2- to 9-fold increased risk of developing cardiovascular
disease (CVD) later in life.1 This most likely results from the
abundance of cardiovascular risk factors, such as hyperten-
sion and obesity, in these women.2–5 The conventional
approach to CVD prevention is to optimize classical risk
factors such as hypertension and diabetes mellitus. However,
communication of CVD risk to young individuals with a low
absolute 10-year CVD risk is challenging. An alternative
manner for CVD risk communication is to focus on cardio-
vascular health (CVH) as is advocated by the American Heart
Association which developed the CVH score.6 The score
includes 3 health factors (blood pressure, total-cholesterol,
and glucose concentration) and 4 health behaviors (body
mass index [BMI], smoking habit, diet, and physical activity)
each categorized as “poor”, “intermediate” or “ideal” and
weighted accordingly (0, 1, or 2 points, respectively). In the
general population, better CVH is associated with lower CVD
morbidity and mortality and with a smaller carotid intima-
media thickness (CIMT).6 CIMT is a marker of subclinical
atherosclerosis and therefore insightful in women around
reproductive age who are mostly still too young for having any
hard CVD outcomes, such as a myocardial infarction or
stroke.7
For most women, pregnancy is a natural moment to
voluntarily seek medical care and improve physical health,
which makes it a potentially interesting moment to assess
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CVH.8,9 Currently it is not known whether CVH in pregnancy is
related to postpartum subclinical atherosclerosis and CVH
later in life. Assessing and improving CVH in women with a
hypertensive disorder of pregnancy might be even more
beneﬁcial than in women with a normotensive pregnancy as
they are more likely to develop atherosclerosis and CVD later
in life.
The objective of this study was to determine the associ-
ation between early pregnancy CVH and postpartum CIMT and
CVH, in women with a normotensive pregnancy and women
with a hypertensive disorder of pregnancy.
Materials and Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Design and Study Population
This study was embedded in the Generation R Study, a
population-based prospective cohort from early pregnancy
onwards.10,11 Approval was obtained from the Medical Ethics
Committee of Erasmus Medical Center, Rotterdam, the
Netherlands (MEC 198.782/2001/31) and the procedures
followed were in accordance with institutional guidelines.12 All
women included in this study provided written informed
consent to use and publish their data. We included women
with a live born singleton, available data on CVH in early
pregnancy and information on at least 1 of our 2 primary
outcomes 10 years after pregnancy (CIMT or CVH). Women
were excluded when they participated with >1 child (visits
with the second and/or third child were excluded; only
including visits with the ﬁrst child) or when they were
pregnant 10 years after pregnancy. The ﬁnal population for
analysis comprised 1924 women (Figure).
Hypertensive Disorders of Pregnancy
Hypertensive disorders of pregnancy were deﬁned as having
gestational hypertension or preeclampsia in the index preg-
nancy. These outcomes were validated and indexed according
to the 2011 criteria of the International Society for the Study
of Hypertension in Pregnancy. A systolic blood pressure
n = 1924
Women with information on early 
pregnancy CVH score and a 
postpartum carotid intima-media
thickness measurement (n = 1619)
and/or CVH score (n = 1170).
n = 2361
Women with no cardiovascular health score in 
pregnancy.
n = 878
Excluded women who participated with more 
than one child.
n = 1726
Women with no outcome of interest available.
n = 31
Women pregnant during follow-up nine years 
after index pregnancy.
n = 141
Women with no information on pregnancy 
complications.
n = 2840
Excluded women who entered the study after 
early pregnancy.
N = 9901
Women enrolled in The Generation R 
Study. 
Figure. Flowchart. CVH indicates cardiovascular health.
Clinical Perspective
What Is New?
• Women with a hypertensive disorder of pregnancy have an
increased risk of cardiovascular disease later in life.
• Assessing and optimizing their cardiovascular health early in
life, such as in pregnancy, could lead to a longer lifetime
spent in better health and reduce the risk of cardiovascular
disease.
• To our knowledge, this study is the ﬁrst to show that better
cardiovascular health in early pregnancy is already associ-
ated with better cardiovascular health 10 years after
pregnancy and with a smaller carotid intima-media thick-
ness, especially in women with a hypertensive disorder of
pregnancy.
What Are the Clinical Implications?
• Assessing and optimizing cardiovascular health in early
pregnancy could lead to a better cardiovascular health and
carotid intima-media thickness in the long-term.
• This is a relatively easy procedure that might help to reduce
the risk of future cardiovascular disease, especially in
women with a hypertensive pregnancy disorder.
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≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg
after 20 weeks of gestation was classiﬁed as gestational
hypertension or as preeclampsia in case of proteinuria with no
evidence of a urinary tract infection in a random urine
sample.13,14
CVH Metrics and CIMT
The CVH score in early pregnancy (gestational age
13.2 weeks [90% range 10.6, 17.1]) included information on
blood pressure, BMI, smoking-habit, and non-fasting total-
cholesterol, and glucose concentrations. Information on
physical activity and dietary intake was not available in such
matter as required for constructing the CVH score. Blood
pressure was measured in sitting position in the right upper
arm with the validated Omron 907 automated digital
oscillometric sphygmomanometer (OMRON Healthcare Eur-
ope B.V., Hoofddorp, the Netherlands) by trained assistants
wearing normal clothing (no white coats). The mean value of 2
blood pressure readings over a 60-second interval was
documented.15 BMI (kg/m2) was calculated after measuring
maternal height (cm) and weight (kg) without shoes. Infor-
mation on smoking was obtained from a questionnaire. Total-
cholesterol (mmol/L) and glucose (mmol/L) concentrations
were measured from non-fasting EDTA blood samples. Sample
processing and storage procedures have been described
previously.11
We assessed postpartum CVH 10 years after pregnancy
(90% range 10.0, 10.8 years). Blood pressure was measured
in supine position in the right upper arm with the validated
automatic sphygmomanometer Datascope Accutorr Plus
(Paramus, NJ).16 The average of the last 3 out of 4 blood
pressure measurements was used for further analyses. BMI
(kg/m2) was derived from maternal height (cm) and weight
(kg) without shoes. Information on smoking, diet, and physical
activity was obtained from questionnaires. Non-fasting total-
cholesterol (mmol/L) concentration measured from plasma
samples 6 years after pregnancy was used as a proxy for
total-cholesterol concentration 10 years after pregnancy.
Detailed information on storage and processing has been
described previously.17 Non-fasting glucose concentration
(mmol/L) was measured 10 years after pregnancy through a
ﬁnger-prick test with the HemoCue Glucose 201 DM System
(HemoCue, Angelholm, Sweden).18
CIMTwasmeasured 3 times at both common carotid arteries
with the Logix E9 ultrasound device (General Electric Health-
care, Wauwatosa, WI), 10 years after pregnancy. CIMT readers
were masked to CVH status and information about the index
pregnancy. The average of all measurements was standardized
for age and blood pressure by 2 graders and used for further
analyses. There was good agreement between both graders
with an intraclass correlation coefﬁcient of 0.91.
Both in pregnancy and 10 years after, each CVH metric
was categorized as poor, intermediate, or ideal and weighted
accordingly (0, 1, and 2 points, respectively). The CVH score
in early pregnancy included 5 metrics and ranged from 0 to 10
points. The postpartum CVH score included 7 metrics and
ranged from 0 to 14 points, in accordance with the CVH score
created by the American Heart Association.6 Having <5 ideal
CVH metrics was deﬁned as low CVH. Details on the
computation of the CVH score are provided in Table 1 and
Data S1.
Covariates
Information on maternal age and gestational age was
obtained during the measurements of the early pregnancy
CVH metrics.13 Information on pre-pregnancy BMI, smoking,
education level, ethnicity, pre-pregnancy hypertension, dia-
betes mellitus, and hypercholesterolemia, gestational dia-
betes mellitus, medication intake (antihypertensive
medication, glucose, and cholesterol regulation medication),
CVD, and menopause was obtained through questionnaires in
pregnancy and during follow-up. Information on pregnancies
before and after the index pregnancy was obtained through an
interview 10 years after pregnancy.
Statistical Analyses
We examined the distribution of pregnancy and follow-up
characteristics for all women with a normotensive preg-
nancy and those with a hypertensive disorder of pregnancy,
and with one of our 2 outcomes of interest (Tables 2 and
3). The presented P values are the result of Student t test
for variables with a normal distribution, the Kruskal–Wallis
test for variables with a skewed distribution and Chi square
test and Fisher exact test for categorical variables. We
imputed missing values in confounders that were used for
linear and logistic regression analyses. To identify whether
the data were missing at random we conducted a Little’s
Missing Completely At Random test, which was not
signiﬁcant (P value: 0.783), indicating data were missing
completely at random. We used the Markov Chain Monte
Carlo multiple imputation procedures to reduce potential
bias attributable to missing data.19 This method assumes no
monotone missing pattern. Data were analyzed in each set
separately, and pooled estimates from the 5 imputed data
sets were used to report the effect estimates and their 95%
CI. For the multiple imputation procedure we performed 10
iterations.20 In this study 1.4% of women had missing
information on education level, 0.21% on ethnicity, and
10.1% on gravidity during follow-up. We tested the robust-
ness of the imputation procedure by comparing our results
based on analyses with imputed confounders to our results
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based on analyses with non-imputed confounders. No
differences were observed.
Because of the skewed distribution of the postpartum CVH
score, we applied a quadratic transformation to this outcome.
To facilitate the interpretation of our ﬁndings we used
z-scores for the quadratic postpartum CVH score. To relate
early pregnancy CVH to postpartum CIMT and CVH we
performed linear and logistic regression analyses (Table 4).
Results are presented for women with a normotensive
pregnancy and those with a hypertensive pregnancy disorder
to highlight potential differences between both groups.
Confounders that were included in the regression models
were selected based on their associations with the exposure
and outcomes of interest and based on previous studies. The
confounders selected included: age and gestational age at
early pregnancy CVH determination, education level, ethnicity,
gravidity during follow-up and time interval between preg-
nancy and follow-up.
A non-response analysis was performed to test for
potential differences in baseline characteristics between
women with an early pregnancy CVH score available and
those who did not (Table S1).
Glucose concentration was obtained non-fasting, whereas
the CVH score requires the inclusion of fasting glucose. To
determine to which extent the inclusion of non-fasting glucose
in and after pregnancy inﬂuenced our results, we performed
sensitivity analyses. Firstly, we reclassiﬁed early pregnancy
(Table S2) and postpartum (Table S3) glucose categories by
using the cutoffs of the International Diabetes Federation for
“ideal” (<7.8 mmol/L), “intermediate” (7.8–11.0 mmol/L)
and “poor” (≥11.1 mmol/L) non-fasting glucose concentra-
tions.21,22 Secondly, we excluded the glucose metric from the
early pregnancy CVH score (Table S2) and postpartum CVH
score (Table S3).
BMI cut-offs for non-pregnant adults were used to
construct the early pregnancy CVH score. This might have
resulted in a misclassiﬁcation of BMI as some women
might have had substantial gestational weight gain by this
time. We attempt to eliminate the inﬂuence of gestational
weight gain and to determine the degree of misclassiﬁca-
tion by replacing early pregnancy BMI with pre-pregnancy
BMI, which was obtained through a questionnaire
(Table S4).
We examined the association between each individual CVH
score metric and the outcomes in women with a previous
normotensive pregnancy and those with a previous hyperten-
sive disorder of pregnancy (Table S5).
To determine the inﬂuence of pregnancy on cardiovas-
cular outcomes we examined the association between a
pre-pregnancy measurement (BMI) and the CVH score and
CIMT after pregnancy over the course of a normotensive
pregnancy and an hypertensive disorder of pregnancy
(Table S6).
Information on diet and physical activity were not available
in pregnancy, but were included in the CVH score after
pregnancy. We tested whether excluding these metrics from
the postpartum CVH score changed our results (data not
shown). We also tested whether having had a hypertensive
disorder of pregnancy before or after the index pregnancy
affected our results by excluding these women from the
analyses (data not shown).
For the statistical analyses we used Statistical Package of
Social Sciences version 24.0 for Windows (SPSS Inc Chicago,
IL).
Results
Table 2 shows the baseline and follow-up characteristics for
women with a normotensive pregnancy and those with a
hypertensive disorder of pregnancy. Women were on average
30.8 years old and 13.2 weeks pregnant when they entered
Table 1. Cardiovascular Health Score Classiﬁcations
Poor (0) Intermediate (1) Ideal (2)
Blood pressure, mm Hg SBP ≥140 and/or DBP ≥90 mm Hg SBP 120 to 139 and/or DBP
80 to 89 mm Hg, or treated to goal
SBP/DBP <120/80 mm Hg
Body mass index, kg/m2 ≥30 kg/m2 25 to 29.99 kg/m2 <25 kg/m2
Smoking Current Former, quit ≤12 months Never/quit >12 months
Diet* (number of ideal food groups) 0 to 1 2 to 3 4 to 5
Physical activity* Inactive Moderately active Active
Total cholesterol, mmol/L ≥6.2 mmol/L 5.2 to 6.2 mmol/L, or treated to goal <5.2 mmol/L
Glucose, mmol/L ≥7.0 mmol/L 5.55 to 7.0 mmol/L, or treated to goal <5.55 mmol/L
DBP indicates diastolic blood pressure; SBP, systolic blood pressure.
*Not included in the cardiovascular health score in early pregnancy.
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Table 2. Maternal Characteristics
Outcomes
Normotensive Pregnancy
n=1786
Hypertensive Disorder of Pregnancy
n=138 P Value*
During index pregnancy
Maternal age, y 30.8 (4.6) 30.8 (4.3) 0.88
Gestational age, wks 13.2 (10.6, 17.1) 12.9 (10.8, 17.4) 0.18
Ethnicity, n (%) 0.48
White 1448 (81.3) 116 (84.1)
African descent 146 (8.2) 9 (6.5)
Asian/South Asian 142 (8.0) 12 (8.7)
Other 46 (2.6) 1 (0.7)
Education, n (%) 0.08
None/primary 107 (5.8) 8 (5.8)
Secondary 717 (40.7) 69 (50.4)
Higher 937 (53.2) 60 (43.8)
First pregnancy, n (%) 883 (49.5) 95 (68.8) <0.001
CVH score, median (90% range) 8.0 (5.0, 10.0) 8.0 (4.0, 10.0) <0.001
Pre-existing hypertension, n (%) 17 (1.0) 0 0.25
Blood pressure, n (%) <0.001
Poor 72 (4.0) 21 (15.2)
Intermediate 596 (33.4) 61 (44.2)
Ideal 1118 (62.6) 56 (40.6)
BMI, n (%) <0.001
Poor 147 (8.2) 24 (17.4)
Intermediate 420 (23.5) 49 (35.5)
Ideal 1219 (68.3) 65 (47.1)
Smoking, n (%) 0.84
Poor 275 (15.4) 20 (14.5)
Intermediate 181 (10.1) 16 (11.6)
Ideal 1330 (74.5) 102 (73.9)
Cholesterol, n (%) 0.61
Poor 145 (8.1) 11 (8.0)
Intermediate 499 (27.9) 44 (31.9)
Ideal 1142 (63.9) 83 (60.1)
Glucose, n (%) 0.02
Poor 14 (0.8) 4 (2.9)
Intermediate 154 (8.6) 16 (11.6)
Ideal 1618 (90.6) 118 (85.5)
During follow-up
Age, y 41.2 (4.6) 41.1 (4.3) 0.88
More than once pregnant, n (%) 1482 (92.4) 104 (83.2) <0.001
Hypertensive disorder of pregnancy† 67 (3.8) 28 (20.3) <0.001
Menopause, n (%) 38 (2.4) 4 (3.1) 0.58‡
Continued
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the study. The majority of women were white and higher
educated. Women with a hypertensive disorder of pregnancy
were more often primiparous and had a worse blood pressure,
BMI, and glucose level in early pregnancy compared with
women with a normotensive pregnancy. Nine years after
pregnancy they had a larger CIMT (588.5 lm [71.7] versus
572.6 lm [70.0]), lower CVH (9.0, 90% range; 5.0, 12.0
versus 10.0, 90% range; 6.0, 13.0), more often <5 ideal CVH
metrics (81.2% versus 62.3%) and a worse blood pressure and
BMI compared with women with a normotensive pregnancy
(Table 3).
In Table 4 we examined the association between the
CVH score in early pregnancy and the CIMT and CVH
score 10-year postpartum, in women with a normotensive
pregnancy and those with a hypertensive disorder of
pregnancy. A higher CVH score in early pregnancy was
associated with a smaller CIMT 10 years after pregnancy
in both groups (5.21 lm [7.40, 3.01], P<0.001 and
9.82 lm [17.98, 1.67], P 0.02, respectively). Table 3
also shows that a higher CVH score in early pregnancy
was associated with a higher postpartum CVH score in
both groups (z-score 0.26 [95% CI: 0.23, 0.30], P<0.001
and z-score 0.25 [95% CI: 0.13, 0.37], P<0.001, respec-
tively) and a lower risk for having <5 ideal postpartum
CVH metrics (RR 0.75 [0.70, 0.80], P<0.001 and 0.70
[0.46, 0.91], P 0.002).
Compared with women with a CVH score in early
pregnancy those without were on average slightly younger
(0.3 years) and they enrolled earlier in pregnancy (0.2 weeks)
(Table S1).
Table S2 shows that the association between early
pregnancy CVH, CIMT, and postpartum CVH remains
unchanged after reclassifying the glucose metric of the CVH
score in early pregnancy according to the International
Diabetes Federation criteria or by excluding the glucose
metric from the early pregnancy CVH score. Also, applying
identical adjustments to the postpartum glucose metric and
thus the postpartum CVH score did not change our main
results (Table S3). Table S4 shows that replacing the BMI
metric of the early pregnancy CVH score by pre-pregnancy
BMI did not change the association between early pregnancy
CVH and postpartum CVH.
We show in Table S5 that smoking and cholesterol level
were the CVH factors strongest associated with CIMT in
women with a previous hypertensive disorder of pregnancy,
whereas in previous normotensive women those were BMI
and blood pressure. The CVH score after pregnancy was
mainly driven by BMI and cholesterol level in women with a
previous hypertensive disorder of pregnancy, whereas in
women without a previous hypertensive disorder of pregnancy
all 5 metrics in pregnancy were associated with the CVH
score after pregnancy.
Table S6 shows that pre-pregnancy BMI is associated with
the CVH score after pregnancy in all women in this study. Pre-
pregnancy BMI is not associated with CIMT after pregnancy in
women with a previous hypertensive disorder of pregnancy,
whereas it is positively associated with CIMT in women with a
previous normotensive pregnancy.
Lastly, excluding the diet and physical activity metrics
from the postpartum CVH score did not change the
association between early pregnancy CVH and postpartum
CVH (data not shown). Also, excluding women who had had
a hypertensive disorder of pregnancy before or after the
index pregnancy did not change the results (data not
shown).
Discussion
This large prospective cohort study shows that better CVH in
early pregnancy is associated with a smaller CIMT, especially
in women with a hypertensive disorder of pregnancy later in
life. Also, better CVH in early pregnancy is associated with
Table 2. Continued
Outcomes
Normotensive Pregnancy
n=1786
Hypertensive Disorder of Pregnancy
n=138 P Value*
Medication, n (%)
Antihypertensive 19 (1.1) 11 (8.0) 0.11
Cholesterol regulating 11 (0.6) 1 (0.7) 1.0‡
Glucose regulating 7 (0.4) 2 (1.4) 1.0‡
Diabetes mellitus, n (%) 12 (0.7) 2 (1.4) 0.29‡
Values are numbers with valid percentages, means (SD) for variables with a normal distribution and medians (90% range) for values with a skewed distribution. Confounders were imputed.
BMI indicates body mass index; CVH, cardiovascular health; n, number.
*The P value is the result of Student t test for variables with a normal distribution, the Kruskal–Wallis test for variables with a skewed distribution and Chi square test for categorical
variables.
†In any other pregnancy than the index pregnancy.
‡Fisher exact test.
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better CVH and a lower risk of having <5 ideal CVH metrics
10 years after pregnancy.
Interpretation of Main Findings
Our ﬁndings on the negative association between CVH in
pregnancy and CIMT are in line with those of a previous study
conducted in 490 American male twins (mean age 55.4
[3.1 years]).23 The study showed that better CVH was
independently associated with a smaller CIMT. Another
American study of 1933 participants with mean age of
597.5 years demonstrated that having ≥3 ideal CVH
metrics was associated with a smaller CIMT.24 Several
studies have compared the CIMT of women with a hyperten-
sive disorder of pregnancy to that of women with a
normotensive pregnancy.25–28 During pregnancy, but also 5
and 25 years after, CIMT was consistently larger in women
with a hypertensive disorder of pregnancy compared with
women with a normotensive pregnancy. Though the underly-
ing pathophysiology of carotid intima-media thickening is
most likely multifactorial, cardiovascular risk factors (or
adverse CVH metrics), such as hypertension, obesity, smok-
ing, a high cholesterol, and diabetes mellitus, have been
identiﬁed as key elements in this process.29,30 The prevalence
of these cardiovascular risk factors is higher amongst women
with a hypertensive disorder of pregnancy compared with
women with a normotensive pregnancy, which might explain
their tendency to a larger CIMT.5,31,32 It seems plausible that
improving adverse CVH metrics early in life will slow down
carotid intima-media thickening and possibly reduce long-
term atherosclerotic risk and CVD risk. Increasing 5 units in
the total CVH score (ranging from 0 to 14) has previously
been associated with a 0.05 mm smaller CIMT.23 We realize
that these and our effect estimates on the association
between early pregnancy CVH and CIMT seem small. Never-
theless, we consider them substantial as even a small
increase in CIMT of 0.1 mm has previously been associated
with a 15% higher risk of developing CVD.33
Table 3. CIMT and CVH 10 Years After Pregnancy
Outcomes
Normotensive
Pregnancy
n=1786
Hypertensive Disorder
of Pregnancy
n=138
P
Value*
CIMT, lm
(mean, SD)
572.6 (70.0) 588.5 (71.7) 0.02
CVH score, median
(90% range)
10.0 (6.0, 13.0) 9.0 (5.0, 12.0) <0.001
Blood pressure,
n (%)
<0.001
Poor 67 (3.8) 24 (17.8)
Intermediate 361 (20.7) 47 (34.8)
Ideal 1313 (75.4) 64 (47.4)
BMI <0.001
Poor 278 (15.6) 40 (29.0)
Intermediate 507 (28.4) 44 (31.9)
Ideal 999 (56.0) 54 (39.1)
Smoking, n (%) 0.41
Poor 248 (15.8) 24 (18.5)
Intermediate 47 (3.0) 6 (4.6)
Ideal 1271 (81.2) 100 (76.9)
Diet, n (%) 0.07
Poor 415 (28.3) 46 (37.7)
Intermediate 965 (65.9) 68 (55.7)
Ideal 85 (5.8) 8 (6.6)
Physical activity,
n (%)
0.82
Poor 52 (3.3) 4 (3.1)
Intermediate 289 (18.4) 21 (16.3)
Ideal 1226 (78.2) 104 (80.6)
Cholesterol, n (%)† 0.35
Poor 133 (8.7) 13 (10.9)
Intermediate 363 (23.6) 33 (27.7)
Ideal 1040 (67.7) 73 (61.3)
Glucose, n (%) 0.42
Poor 397 (26.8) 33 (29.2)
Intermediate 674 (45.4) 55 (48.7)
Ideal 413 (27.8) 25 (22.1)
Ideal CVH
metrics, n (%)
<0.001
0 23 (2.1) 1 (1.2)
1 27 (2.5) 8 (9.4)
2 92 (8.5) 14 (16.5)
3 207 (19.1) 25 (29.4)
4 327 (30.1) 21 (24.7)
5 306 (28.2) 13 (15.3)
Continued
Table 3. Continued
Outcomes
Normotensive
Pregnancy
n=1786
Hypertensive Disorder
of Pregnancy
n=138
P
Value*
6 100 (9.2) 3 (3.5)
7 3 (0.3) 0
Values are numbers with valid percentages, means (SD) for variables with a normal
distribution and medians (90% range) for values with a skewed distribution. BMI indicates
body mass index; CIMT, carotid intima-media thickness; CVH, cardiovascular health.
*The P value is the result of Student t test for variables with a normal distribution, the
Kruskal–Wallis test for variables with a skewed distribution and Chi square test for
categorical variables.
†Measured 6 years after pregnancy.
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CVH Later in Life
Population studies showed that only a minority of individuals
have 7 ideal CVH metrics (0.1%–2.3%), indicating the rarity of
optimal CVH in the general population.6,34,35 Individuals with
fewer ideal CVH metrics are more at risk of developing
CVD.34,35 In our study, the percentage of women with a
hypertensive disorder of pregnancy having <5 ideal CVH
factors after pregnancy was 81.2%. This was substantially
higher compared with that of women aged 20 to 39 years
from the National Health and Nutrition Examination Survey
study, a large population-based study, where 64% of
women had <5 ideal CVH metrics.36 Compared with women
participating in the National Health and Nutrition Examination
Survey study, those with a hypertensive disorder of preg-
nancy more often had a poor blood pressure and glucose
level during and after pregnancy, whereas they were less
often smokers. Total cholesterol was similar between both
studies, with the majority of women having ideal total-
cholesterol concentrations at both time points. Other studies
also showed that women with a hypertensive disorder of
pregnancy have on average a higher blood pressure in early
pregnancy and thereafter.4 Improving blood pressure as early
in pregnancy might help reduce their risk of future hyper-
tension. As blood pressure is closely related to other metrics
of the CVH score, such as BMI and physical activity,
improving the whole CVH score in early pregnancy might
yield a faster reduction in blood pressure than treating blood
pressure alone.37 Our results show that early pregnancy CVH
is closely associated with CVH later in life. This suggests that
women with good CVH in early pregnancy are likely to have
similar CVH after pregnancy. Improving CVH in early
pregnancy will likely result in a longer lifetime spent in
better health, thereby reducing the risk of CVD.38–40 Most
likely, it is even better and more cost effective to improve
CVH before pregnancy, as was demonstrated in previous
studies.41,42 We demonstrate that pre-pregnancy BMI is
associated with CVH and CIMT after pregnancy. Though the
association with CIMT was not signiﬁcant in women with a
previous hypertensive disorder of pregnancy. A possible
explanation for this ﬁnding might be that other factors than
BMI, eg, the hypertensive disorder of pregnancy itself or a
genetic predisposition, are stronger associated with CIMT in
women with a previous HDP. Additionally, we showed that in
women with a previous HDP, cholesterol and smoking were
associated with CIMT and not BMI. Previous studies demon-
strated that smoking and cholesterol are risk factors of
carotid intima-media thickening through an upregulation of
local inﬂammation.43,44 Though optimizing pre-pregnancy
CVH seems useful, the majority of women do not seek
medical help until they are pregnant, which complicates
optimization of preconception health by healthcare providers.
Raising awareness for healthy lifestyle changes, eg, through
government healthcare campaigns and education from a
young age onwards, might improve preconception CVH.45
Improvement of maternal CVH in early pregnancy might also
beneﬁt the offspring by reducing the risk of suboptimal
developmental programming and consequently reducing
predisposition to CVD.46 For most women, pregnancy is a
natural moment to seek medical care. Women are also more
motivated to adapt healthful behavior, with the health of the
offspring being the most important motivator.8,9 Projecting
on the health of the offspring could be an effective method
to frame healthful changes during pregnancy. Healthcare
providers (eg, obstetrician, midwife, or general practitioner)
could assess the CVH score in early pregnancy and motivate
women to adapt healthier lifestyle behaviors, while treating
CVH factors if necessary.
Strengths and Limitations
Results of our study should be interpreted within the context
of some limitations. First, we used total-cholesterol concen-
tration 6 years after pregnancy as a proxy for the cholesterol
metric 10 years after pregnancy because of unavailability of
the latter. A recent study showed that total-cholesterol
concentration remains fairly stable over a 4-year interval for
stable weight individuals.47 Total-cholesterol concentration
slightly decreased in individuals with progressive weight loss
(estimated 0.16 mmol/L per 4 years) and progressive weight
gain (estimated 0.21 mmol/L per 4 years). As we used a
Table 4. The Association Between CVH in Early Pregnancy and CIMT and CVH 10 Years After Pregnancy
Outcomes 10 Years After Pregnancy
Normotensive Pregnancy Hypertensive Disorder of Pregnancy
CVH in Early Pregnancy P Value CVH in Early Pregnancy P Value
CIMT, lm (Beta, 95% CI) 5.21 (7.40, 3.01) <0.001 9.82 (17.98, 1.67) 0.02
CVH score (Z-score) 0.26 (0.23, 0.30) <0.001 0.25 (0.13, 0.37) <0.001
<5 ideal CVH metrics, RR (95% CI) 0.75 (0.70, 0.80) <0.001 0.70 (0.46, 0.91) 0.002
Values are regression coefﬁcients and are based on linear and logistic regression analysis. Beta coefﬁcients and relative risks represent the change in outcome per one point increase in
the early pregnancy CVH score. Values were adjusted for: age and gestational age at early pregnancy CVH determination, education level, ethnicity, and gravidity during index pregnancy.
CIMT indicates carotid intima-media thickness; CVH, cardiovascular health; RR, relative risk.
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3 years interval between measuring total-cholesterol concen-
tration and the other CVH metrics and only 6.6% of the total
population showed progressive weight gain/loss (data not
shown), we feel conﬁdent that using this proxy will not have
inﬂuenced our results substantially. Second, we used non-
fasting glucose concentrations to calculate the CVH scores
whereas the AHA designed the score with fasting glucose
concentrations. As a result, more women were grouped in the
“poor” category for this CVH metric both in and after
pregnancy. To determine the effect of using non-fasting
glucose concentrations, we performed 2 sensitivity analyses
(1) after reclassifying the glucose metric according to the
International Diabetes Federation criteria for “ideal”, “inter-
mediate” and “poor” non-fasting glucose concentrations and
(2) after excluding the glucose metric from our CVH score.
The absolute CVH scores changed in both analyses. However,
the strength and direction of all associations remained the
same. Third, we applied BMI cut-offs for non-pregnant adults
to construct the early pregnancy CVH score. As the mean
gestational age of the early pregnancy CVH score was
13.2 weeks (90% range 10.6, 17.1), some women might have
had substantial gestational weight gain by this time. This
might have resulted in a misclassiﬁcation of BMI. However,
replacing early pregnancy BMI by pre-pregnancy BMI (ob-
tained through a questionnaire) did not change our main
results (Table S4). Fourth, we observed some differences
between women with and without a CVH score in pregnancy.
Some cardiovascular risk factors were more favorable in
women without a CVH score available in pregnancy (blood
pressure and smoking status), whereas others (BMI and
education level) were more disadvantageous in these women.
Including women with a poorer blood pressure and smoking
status in our study might have positively inﬂuenced the
strength of our results, but not the differences of the
observed associations between women with a previous
normotensive pregnancy and those with a previous hyper-
tensive disorder of pregnancy. Fifth, similar to most popula-
tion studies, we did not perform preconceptional
measurements. Therefore, we cannot exclude the possibility
that CIMT was already larger before pregnancy in women with
a hypertensive disorder of pregnancy. Nevertheless, the CVH
score in early pregnancy was associated with postpartum
CIMT and will in practice be relatively easy and cheap to
calculate, as opposed to CIMT for which an ultrasound device
is required, during a point in life at which women naturally
seek health care. Sixth, the CVH score was designed for the
general population. This is the ﬁrst study to examine the CVH
score in pregnant women. Results should therefore be
interpreted with caution until future studies have replicated
similar results. Lastly, results might not be generalizable to all
ethnicities as the majority of women in our study were white
(81.4%).
Conclusions
Better CVH in pregnancy is associated with less subclinical
atherosclerosis after pregnancy and better CVH 10 years
after pregnancy. This is relevant for all women, but especially
in those with a hypertensive disorder of pregnancy. Improving
CVH in early pregnancy will likely result in a longer lifetime
spent in better health, thereby reducing the risk of CVD. As
pregnancy is an incentive for women to improve lifestyle,
future studies should evaluate whether the CVH score in
pregnancy is useful for early cardiovascular counseling to
optimize CVH.
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Data S1. 
 
The CVH score in pregnancy included five metrics (blood pressure, BMI, smoking, total-
cholesterol concentration and glucose concentration). The postpartum CVH score was 
defined according to the classification of the American Heart Association by combining 
seven health metrics (blood pressure, BMI, smoking, diet, physical activity, total-cholesterol 
concentration and glucose concentration). For each metric, women were grouped into the 
poor (0 points), intermediate (1 point) or ideal (2 points) category. The corresponding points 
of all seven metrics created the CVH score in early pregnancy (ranging from 0 to 10) and 
postpartum (ranging from 0 to 14). Each metric had the same weight. Women were 
categorized one group lower for the metrics blood pressure, total-cholesterol and glucose 
when they received treatment for hypertension, hypercholesterolemia or diabetes (e.g. from 
ideal to intermediate group for blood pressure). Consequently, these women could not obtain 
an ideal score for these metrics. The diet metric included five food groups. Women could 
obtain 1 point for each ideal food group, with a total of five points for an ideal diet. Ideal 
food groups included: ≥4.5 cups of fruit and vegetables per day, < 1500mg sodium per day, 
≥3 servings of 1 ounce fiber-rich whole grains per day, ≤450 kcal of sugar-sweetened 
beverages per week and ≥2 servings of fish per week. Physical activity was classified as 
inactive, moderately active (1-149 minutes per week moderately active or 1-74 minutes per 
week vigorously active) and active (≥150 minutes per week moderately active or ≥75 minutes 
per week vigorously active).  
The total number of postpartum CVH metrics categorized as ideal created a separate 
score, ranging from 0 to 7. Less than five ideal postpartum CVH metrics was defined as low 
CVH. 
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Table S1. Comparison of women with and without a CVH score in early pregnancy.  
Characteristics during index  
pregnancy 
Women with  
CVH score 
(n=5199) 
Women without  
CVH score 
(n=3822) 
P-value 
Maternal age, years 29.7 (5.1) 29.8 (5.6) 0.13 
Gestational age, weeks 13.4 (10.6, 17.2) 15.8 (11.1, 24.8) <0.001 
Ethnicity, n (%)   <0.001 
Caucasian 2868 (75.6) 3278 (71.7)  
African descent 430 (11.3) 682 (14.9)  
Asian/South Asian 367 (9.7) 438 (9.6)  
Other 127 (3.3) 173 (3.8)  
Education, n (%)   <0.001  
  None/primary 357 (9.6) 548 (13.3)  
Secondary 1753 (47.1) 1950 (47.2)  
  Higher 1612 (43.3) 1629 (39.5)  
First pregnancy, n (%) 1833 (48.1) 2185 (44.3) <0.001 
Blood pressure, n (%)   0.004 
Poor 227 (5.9) 193 (4.5)  
Intermediate 1273 (33.3) 1367 (31.9)  
Ideal 2322 (60.8) 2726 (63.6)  
BMI, n (%)    <0.001 
Poor 429 (11.2) 651 (15.1)  
Intermediate 941 (24.6) 1266 (29.4)  
Ideal 2452 (64.2) 2390 (55.5)  
Smoking, n (%)   0.02 
Poor 739 (19.3) 670 (17.6)  
Intermediate 385 (10.1) 342 (9.0)  
Ideal 2698 (70.6) 2800 (73.5)  
Cholesterol, n (%)    0.06 
Poor 291 (7.6) 35 (6.5)  
Intermediate 1052 (27.5) 124 (22.9)  
Ideal 2479 (64.9) 383 (70.7)  
Glucose, n (%)    0.12 
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Poor 40 (1.0) 31 (1.6)  
Intermediate 344 (9.0) 186 (9.6)  
Ideal 3438 (90.0) 1720 (88.8)  
 
BMI, body mass index; EP-CVH, early pregnancy cardiovascular health; PP-CVH, 
postpartum cardiovascular health. Values are numbers with valid percentages, means (SD) 
for variables with a normal distribution and median (90% range) for values with a skewed 
distribution.  
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Table S2. The association between the CVH score in early pregnancy, CIMT and the postpartum CVH score when glucose in pregnancy 
is classified according to the IDF criteria or excluded from the early pregnancy CVH score.  
Outcome  CVH score in early 
pregnancy according 
to the IDF criteria 
P-value CVH score in early  
Pregnancy excluding  
glucose 
P-value  
CIMT, μm (Beta, 95% CI) -5.52 (-7.67, -3.37) <0.001 -5.78 (-7.98, -3.58) <0.001  
Postpartum CVH score 
(Beta, 95% CI) 
0.26 (0.23, 0.30) <0.001 0.26 (0.23, 0.30) <0.001  
 
CIMT, carotid intima-media thickness; CVH, cardiovascular health; IDF, International Diabetes Federation. Values are regression coefficients 
(beta) with corresponding 95% CI and are based on linear regression analysis. Beta coefficients represent the change in outcome per one point 
increase in the early pregnancy CVH score. Values were adjusted for: age and gestational age at early pregnancy CVH determination, 
educational level, ethnicity, years after pregnancy and gravidity after pregnancy.  
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Table S3. The association between the CVH score in early pregnancy and the 
postpartum CVH score when postpartum glucose is classified according to the IDF 
criteria or excluded from the postpartum CVH score. 
Outcomes  CVH score in early 
pregnancy 
P-value  
Postpartum CVH according to the IDF criteria 0.27 (0.23, 0.30) <0.001  
(Beta, 95% CI)    
Postpartum  CVH excluding glucose 0.28 (0.25, 0.31) <0.001  
 (Beta, 95% CI)    
 
CVH, cardiovascular health; IDF, International Diabetes Federation.  
Values are regression coefficients (beta) with corresponding 95% CI and are based on linear 
regression analysis. Beta coefficients represent the change in outcome per one point increase 
in the early pregnancy CVH score. Values were adjusted for: age and gestational age at early 
pregnancy CVH determination, educational level, ethnicity, years after pregnancy and 
gravidity after pregnancy.  
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Table S4. The association between the CVH score in early pregnancy and the 
postpartum CVH score when pre-pregnancy BMI is used to categorize the early 
pregnancy CVH score. 
 
Outcomes ten years after pregnancy CVH score in early 
pregnancy 
P-value  
CVH score (Beta, 95% CI) 0.26 (0.22, 0.30) <0.001  
 
CVH, cardiovascular health.  
Values are regression coefficients (beta) with corresponding 95% CI and are based on linear 
regression analysis. Beta coefficients represent the change in outcome per one point increase 
in the early pregnancy CVH score. Values were adjusted for: age and gestational age at early 
pregnancy CVH determination, educational level, ethnicity, years after pregnancy and 
gravidity after pregnancy.  
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Table S5. The association between the individual metrics of the CVH score in early pregnancy and CIMT and CVH ten years after 
pregnancy.  
Outcomes ten years after pregnancy Normotensive pregnancy Hypertensive disorder of pregnancy 
 Exposure in pregnancy P-value Exposure in 
pregnancy 
P-value 
 Smoking   Smoking  
CIMT, μm (Beta, 95% CI) -2.84 (-7.38, 1.69) 0.22 -19.76 (-36.10, -3.42) 0.02 
CVH score, (Z-score) 0.33 (0.25, 0.41) <0.001 0.04 (-0.27, 0.34) 0.82 
< 5 ideal CVH metrics, RR (95% CI) 0.73 (0.64, 0.82) <0.001 0.80 (0.42, 1.08) 0.43 
 BMI  BMI  
CIMT, μm (Beta, 95% CI) -12.07 (-17.28, -6.85) <0.001 -0.03 (-17.01, 16.95) 0.98 
CVH score, (Z-score) 0.46 (0.37, 0.56) <0.001 0.46 (0.19, 0.72) 0.001 
< 5 ideal CVH metrics, RR (95% CI) 0.46 (0.37, 0.58) <0.001 0.42 (0.10, 0.91) 0.01 
 Blood pressure  Blood pressure  
CIMT, μm (Beta, 95% CI) -12.77 (-18.26, -7.28) <0.001 3.67 (-15.18, 22.52) 0.70 
CVH score, (Z-score) 0.12 (0.03, 0.22) 0.01 0.29 (-0.03, 0.60) 0.08 
< 5 ideal CVH metrics, RR (95% CI) 0.82 (0.72, 0.91) <0.001 0.79 (0.46, 1.03) 0.11 
 Cholesterol  Cholesterol  
CIMT, μm (Beta, 95% CI) -0.67 (-3.27, 1.93) 0.80 -22.32 (-41.05, -3.59) 0.03 
CVH score, (Z-score) 0.38 (0.29, 0.48) <0.001 0.45 (0.14, 0.75) 0.004 
< 5 ideal CVH metrics, RR (95% CI) 0.78 (0.68, 0.87) <0.001 0.76 (0.44, 1.02) 0.09 
 Glucose  Glucose  
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CIMT, μm (Beta, 95% CI) -8.05 (-17.88, 1.78) 0.11 -19.61 (-47.25, 8.03) 0.17 
CVH score, (Z-score) 0.34 (0.13, 0.54) 0.001 0.29 (-0.27, 0.84) 0.31 
< 5 ideal CVH metrics, RR (95% CI) 0.76 (0.58, 0.97) 0.02 0.72 (0.18, 1.14) 0.32 
 
CIMT, carotid intima-media thickness; CVH, cardiovascular health; RR, relative risk. Values are regression coefficients and are based on linear 
and logistic regression analysis. Beta coefficients and odds ratios represent the change in outcome per one point increase in the early pregnancy 
CVH score. Values were adjusted for: age and gestational age at early pregnancy CVH determination, educational level, ethnicity and gravidity 
during index pregnancy. 
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Table S6. The association between pre-pregnancy BMI and CIMT and CVH ten years after pregnancy.  
Outcomes ten years after pregnancy Normotensive pregnancy Hypertensive disorder of pregnancy 
 Pre-pregnancy BMI P-value Pre-pregnancy BMI P-value 
CIMT, μm (Beta, 95% CI) 1.88 (0.96, 2.81) <0.001 0.14 (-2.67, 2.96) 0.92 
CVH score, (Z-score) -0.08 (-0.09, -0.06) <0.001 -0.07 (-0.11, -0.03) 0.002 
< 5 ideal CVH metrics, RR (95% CI) 1.1 (1.08, 1.12) <0.001 1.05 (1.0, 1.08) 0.05 
 
CIMT, carotid intima-media thickness; CVH, cardiovascular health; RR, relative risk. Values are regression coefficients and are based on linear 
and logistic regression analysis. Beta coefficients and odds ratios represent the change in outcome per one point increase in the early pregnancy 
CVH score. Values were adjusted for: age and gestational age at early pregnancy CVH determination, educational level, ethnicity and gravidity 
during index pregnancy. 
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